Niagen Bioscience (NAGE) Asset Writedowns and Impairment (2016 - 2026)
Niagen Bioscience (NAGE) posted quarterly Asset Writedowns and Impairment of $85000.0 for Q1 2026, up 106.43% year-over-year from $41175.3 in Q1 2025, and up 214.81% quarter-over-quarter from $27000.0 in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) Asset Writedowns and Impairment (2016 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Asset Writedowns and Impairment for 11 consecutive years, with $85000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment rose 106.43% year-over-year to $85000.0; the TTM figure through Mar 2026 stood at $189000.0 (up 107.24% YoY), while the FY2025 annual figure was -$1.2 million, up 3.03% from the prior year.
- Asset Writedowns and Impairment grew to $85000.0 in Q1 2026 per NAGE's latest filing, from $27000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $400000.0 in Q2 2023 and bottomed at -$1.3 million in Q1 2025.
- Historically, Asset Writedowns and Impairment has averaged -$141941.2 across 5 years, with a median of $12000.0 in 2024.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment soared 8100.0% — and 2025, when it plunged 3874.29%.
- Niagen Bioscience's Asset Writedowns and Impairment stood at -$28000.0 in 2022, then tumbled by 3264.29% to -$942000.0 in 2023, then sank by 39.49% to -$1.3 million in 2024, then jumped by 102.05% to $27000.0 in 2025, then jumped by 214.81% to $85000.0 in 2026.
- Business Quant data shows NAGE's Asset Writedowns and Impairment at $85000.0 in Q1 2026, $27000.0 in Q4 2025, and -$12000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -66,000.00 |
| Mar 31, 2026 | 85,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Jun 30, 2025 | 89,000.00 |
| Mar 31, 2025 | -1.32 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 400,000.00 |
| Mar 31, 2023 | 316,000.00 |
| Dec 31, 2022 | 35,000.00 |
| Sep 30, 2022 | 23,000.00 |
| Jun 30, 2022 | -5,000.00 |
| Mar 31, 2022 | 10,000.00 |
| Dec 31, 2021 | 198,000.00 |
| Sep 30, 2021 | -178,000.00 |